Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
Emjenta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Pharmacology:
Emjenta combines two antihyperglycemic agents:
-
Empagliflozin: A sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion.
-
Linagliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner.
Dosage & Administration:
The recommended dose is one tablet of Emjenta 10/5 mg taken orally once daily, with or without food. Dosage may be adjusted based on individual patient response and tolerability.
Interaction:
Caution is advised when co-administering with insulin or insulin secretagogues due to the increased risk of hypoglycemia. Monitor for signs of dehydration when used with diuretics.
Contraindications:
Emjenta is contraindicated in patients with:
-
Hypersensitivity to Empagliflozin, Linagliptin, or any component of the formulation.
-
Severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease, or dialysis.
Side Effects:
Common side effects may include:
-
Urinary tract infections
-
Genital mycotic infections
-
Nasopharyngitis
-
Cough
-
Hypoglycemia (especially when used with insulin or sulfonylureas)
Serious side effects:
-
Ketoacidosis
-
Pancreatitis
-
Hypersensitivity reactions
Pregnancy & Lactation:
Emjenta is not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal renal development. Breastfeeding is not advised while on this medication as Empagliflozin may affect postnatal renal development in infants.
Precautions & Warnings:
-
Monitor renal function before and during treatment.
-
Assess for signs of ketoacidosis, especially during periods of stress, surgery, or reduced caloric intake.
-
Use caution in patients with a history of pancreatitis.
-
Elderly patients may be at increased risk for volume depletion; monitor for signs of hypotension.
Therapeutic Class:
Combination of SGLT2 inhibitor and DPP-4 inhibitor.
Storage Conditions:
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Change Language